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ABSTRACT
Background The effectiveness of endovascular 
treatment (EVT) for large vessel occlusion (LVO) stroke 
severely depends on time to treatment. However, it 
remains unclear what the value of faster treatment is in 
the years after index stroke. The aim of this study was to 
quantify the value of faster EVT in terms of health and 
healthcare costs for the Dutch LVO stroke population.
Methods A Markov model was used to simulate 
5- year follow- up functional outcome, measured with 
the modified Rankin Scale (mRS), of 69- year- old LVO 
patients. Post- treatment mRS was extracted from the 
MR CLEAN Registry (n=2892): costs per unit of time 
and Quality- Adjusted Life Years (QALYs) per mRS sub- 
score were retrieved from follow- up data of the MR 
CLEAN trial (n=500). Net Monetary Benefit (NMB) at a 
willingness to pay of €80 000 per QALY was reported 
as primary outcome, and secondary outcome measures 
were days of disability- free life gained and costs.
Results EVT administered 1 min faster resulted in 
a median NMB of €309 (IQR: 226;389), 1.3 days 
of additional disability- free life (IQR: 1.0;1.6), while 
cumulative costs remained largely unchanged (median: 
-€15, IQR: −65;33) over a 5- year follow- up period. As 
costs over the follow- up period remained stable while 
QALYs decreased with longer time to treatment, which 
this results in a near- linear decrease of NMB. Since 
patients with faster EVT lived longer, they incurred more 
healthcare costs.
Conclusion One- minute faster EVT increases QALYs 
while cumulative costs remain largely unaffected. 
Therefore, faster EVT provides better value of care at no 
extra healthcare costs.
INTRODUCTION
Occlusions of the intracranial carotid artery and 
middle cerebral artery, commonly referred to as 
large vessel occlusions (LVO), are severe causes of 
acute ischemic stroke (AIS), frequently resulting in 
persisting neurological deficits affecting patients’ 
health and healthcare costs.1–3 Mortality of the 
LVO stroke population is high and a large portion 
of the survivors remain dependent on care.2 3 These 
outcomes have drastically improved in recent years 
with the introduction of endovascular treatment 
(EVT).4 The beneficial effect of EVT is, however, 
highly time- dependent.5 As a result, various poli-
cies that aim at reducing time delay from onset of 
neurologic deficit to EVT have been investigated.6 
However, it remains unclear what the health and 
cost effects of faster EVT are in the years following 
treatment.
Health outcomes and costs have a strong associ-
ation in the case of LVO stroke as the high disease 
burden results in a lower perceived quality of life and 
higher demand on healthcare facilities.3 7 Besides 
the short- and long- term health benefits, several 
studies have proven that EVT reduces healthcare 
costs in the years after treatment.4 8 9 Although EVT 
has become standard practice in developed coun-
tries worldwide,10 various time- consuming inef-
ficiencies remain present in current practice.11 12 
With the growing use of advanced diagnostics the 
negative side- effects in terms of added delay to 
treatment should be known.13 With several poli-
cies aiming at faster EVT delivery, proposed and 
promising yet time- consuming advanced diagnos-
tics available,6 13 so understanding the value of each 
minute has become increasingly important.
Studies that evaluate workflow improvements 
mainly used time saved as primary outcome and thus 
do not include long- term health and cost effects.6 A 
recent study determined the health and cost effects 
of faster EVT in the case of LVO stroke based on 
US guidelines and data.14 However, extrapolation 
of US data on a population level to the Netherlands 
and other European countries is difficult: besides 
differences in healthcare costs, geographical differ-
ences cause different onset to EVT times,15 16 and US 
guidelines apply stricter imaging selection criteria 
for EVT eligibility.17 18 The use of similar guidelines 
and empirical findings suggest that Dutch data is 
more comparable to other European countries.19 
Furthermore, the adaptation of the guidelines in the 
US is not universal, resulting in a more comparable 
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situation in regions of the US to the Dutch setting. The aim of 
this study was to quantify the value of faster EVT in terms of 
health and healthcare costs for the Dutch LVO stroke population 
with a Markov model.
METHODS
In this study, simulations with a Markov model were performed 
to compute expected health and costs during follow- up for each 
hour of delay to EVT of patients with intracranial carotid artery, 
M1, and proximal M2 occlusions. Subsequently, the differences 
in health and cost outcomes between each hour of delay was 
used to represent the effect of faster EVT per minute.
Modeling procedure
A two- staged Markov model was developed with a short- term 
and long- term part. For each time step, simulated patients could 
be in one of six Markov states defined by modified Rankin 
Scale (mRS) sub- scores: mRS 0 and 1 were combined in one 
Markov state since the sample size was otherwise too low to 
retrieve accurate estimates. The mRS is a seven- point scale for 
disability, ranging from 0 (no disabilities) to 6 (death). The short- 
term model was used to simulate 90- day mRS per hour delay of 
time from onset to the start of EVT, which was defined by the 
time of groin puncture. Time to groin puncture was preferred 
to time to end- of- intervention as the resulting time related mRS 
would include an effect related to LVO and thus intervention 
complexity: furthermore it is unlikely that intervention time can 
be saved to achieve faster EVT. Simulated cohorts were assumed 
to exist of an even split of males and females aged 69, the median 
age of patients in the MR CLEAN registry,15 at the beginning of 
the long- term simulations deterioration of mRS could only occur 
after stroke recurrence or due to death. In the long- term model 
changes in mRS due to stroke recurrence and all- cause mortality 
were simulated over 5 years of follow- up with a cycle length of 
1 year. Figure 1 contains the short- and long- term model archi-
tecture graphically. Quality- adjusted life years (QALYs) and costs 
related to each Markov state were discounted at a 1.5% and 
4% compounded annual rate, respectively, according to Dutch 
guidelines for cost effectiveness research.20 A yearly inflation 
rate of 1.7% was used to adjust future costs based on fore-
casts from the Dutch Ministry of Health, Welfare and Sport.21 
TreeAge software (TreeAge Pro 2019, version R2.1; TreeAge, 
Williamstown MA, USA) was used for implementing the model 
and simulations.
Data sources
Input parameters of the Markov model were retrieved retrospec-
tively from the MR CLEAN Registry part 1 and 2,15 and 2- year 
follow- up data from the MR CLEAN trial,22 23 public data,24 
and literature.25 26 Patients from the MR CLEAN Registry were 
included based on the following criteria: LVO in the anterior 
circulation, treatment in MR CLEAN trial center, age ≥18 years, 
available 90- day mRS, available time from onset to groin punc-
ture, and time from onset to groin puncture ≤360 min (figure 2). 
The data collection protocols have been published, and ethics 
committee and research board approval has previously been 
received in compliance with the Declaration of Helsinki.15 27 28
Probabilities
The data of 2892 patients in the MR CLEAN Registry were used 
to retrieve the per- hour of time from onset to groin puncture and 
Figure 1 Markov model architecture: Pane A: Short- term model used 
for each hour to simulate 90- day mRS (modified Rankin Scale). In this 
example, 0–60 minutes of onset time to groin puncture was presented. 
Pane B: Long- term model for patients (example for mRS 3 at 90- days' 
post- index stroke). After recurrent stroke an equal or higher mRS score 
can be achieved. After stroke recurrence, death (mRS 6) is not possible 
to prevent duplicate mortality rates in the model. mRS after stroke 
recurrence was based on normalized values from the MR CLEAN trial 
control arm.
Figure 2 Data and inclusion. In this study data from the MR CLEAN 
Registry (part 1 and 2), MR CLEAN trial, and 2- year follow- up from the 
MR CLEAN trial were used. For this study, additional exclusion criteria 
were formulated for the MR CLEAN Registry data. EVT, endovascular 
treatment; mRS, modified Rankin Scale.  on M
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the probability of mRS sub- scores 90 days after EVT (figure 1A). 
Yearly mortality rates of the Dutch population by age and gender 
were retrieved from forecasts of the Royal Dutch Actuarial Society 
starting in 2021.24 Subsequently, published hazard rates (HR) of 
additional mortality related to mRS and years after index stroke 
were used to compute all- cause, including recurrent stroke- related, 
mortality rates.25 The probability of a recurrent stroke for each year 
after an index stroke was retrieved from a population study.26 To 
prevent double inclusion of stroke- related mortality in the model, 
death (mRS 6) was not modeled as an outcome after recurrent 
stroke. Instead, the HR by Hong et al on all- cause mortality was 
used, which included recurrent stroke- related mortality and other 
causes of death.25 Functional outcome at 90 days excluding death 
(mRS6) of the MR CLEAN trial control arm (n=267) was used to 
compute the mRS distribution after stroke recurrence (figure 1).22 
As death could not occur and mRS could only remain equal or dete-
riorate, the outcomes of the MR CLEAN trial control arm were 
normalized for the available outcome options (online supplemental 
table S1).
Costs and QALYs
Two- year follow- up data of the MR CLEAN trial (n=391) was 
used to estimate QALYs and costs per unit of time in separate 
mRS sub- scores. Data was collected at 3, 6, 12, 18, and 24 
months' post- index stroke and included utility scores computed 
from EuroQoL 5D and cost questionnaires. A QALY gener-
ally is a value between 0 and 1 where 0 implies death and 1 
perfect health during 1 year. However, in our reference data it 
was also possible to have a negative QALY since some health 
situations were perceived by the patients as worse than death. 
Per patient, the average of each mRS/utility score combination 
across different time points was used as the QALY estimate. The 
online supplemental material contains more information on the 
data collection and computations with costs and utility scores 
previously collected by van den Berg et al.27 In short, costs were 
computed from a healthcare payer perspective and included: 
acute setting treatment cost, in- hospital costs, outpatient clinic 
visits, rehabilitation, formal homecare, and long- term institu-
tionalized costs. The mRS at 90 days and 18 months were used 
as reference points for the calculation of costs per mRS- related 
health state for the first and second year after index AIS, respec-
tively. Follow- up costs per mRS from the third year onward were 
assumed equal to costs of the second year excluding rehabilita-
tion costs (online supplemental table S1). Mean costs and QALY 
values were used to perform baseline simulations. Historical 
inflation rates from the Dutch Central Bureau of Statistics were 
used to adjust the reported costs with reference year 2015 to the 
reference simulation start year of this study (2021).27
Sensitivity analyses
One- way sensitivity analyses were performed to assess the degree 
of change in outcome due to change of a single input parameter. 
Outcome measures were reported for an increase and decrease 
of 10% with respect to the baseline input parameters. For age of 
the simulated population, a deviation of 4 years from the baseline 
age was used. Deviations in age were only used in the long- term 
model, but the effect of age on 90- day mRS was not included 
in this study. A probabilistic sensitivity analysis was performed 
to assess input parameter uncertainty. Online supplemental 
table S1 includes the distribution type per input parameter. 10 
000 s order Monte Carlo simulations were used to estimate the 
certainty of the estimates. External validation with respect to 
simulated mRS and reported mRS in contemporary follow- up 
data of endovascular treated patients was performed.23 29 30 In 
the external validation the proportion of patients with good 
functional outcome (mRS ≤2), poor functional outcome but 
not deceased (mRS 3–5), or death (mRS 6) were compared with 
follow- up results from REVASCAT (1 year),29 MR CLEAN (2 
years),23 and a study by Clua- Espuny et al (5 years).30
Population effects
An estimate was made to represent the effects of 1 min of faster 
EVT for the Dutch population based on the PSA results. For this 
estimate the total population in the MR CLEAN registry part 1 
and 2 (n=3279) included in 43 months was used to compute the 
yearly number of LVO patients that receive EVT (n=887) and 
thus could benefit from faster EVT. The outcome on the popula-
tion level was computed by taking a weighted average based on 
the prevalence of each hour delay to groin puncture in the MR 
CLEAN registry.
Outcome measures
The primary outcome measures used were Net Monetary Value 
(NMV), a single aggregated value for costs, and QALYs where 
QALYs are converted to a monetary value NMV=QALYs*will-
ingness to pay - costs, per hour delay from onset to groin punc-
ture, and Net Monetary Benefit (NMB, the NMV difference 
between each hour): at a willingness to pay threshold of €80 
000 per QALY.20 Secondary outcome measures were QALYs 
and costs. Results were presented as cumulative values over the 
5- year simulated period. Outcome measures were computed per 
hour delay of time from onset to groin puncture and reported 
for 1 min, 10 min, and 1 hour of faster EVT. Differences in 
outcome measures between the hours were used to compute 
outcome measures of faster EVT. Transforming outcomes per 
hour of faster EVT to per minute includes an assumption of 
constant differences between hours. Per minute of faster EVT, 
additional days of disability- free life (additional days in perfect 
health; QALYs/365), change in costs, and NMB were computed. 
PSA results were reported as median with IQR. For descriptive 
statistics (online supplemental table S2) distributions across 
the 6- hour delay were statistically compared with ANOVA, 
Kruskall–Wallis, and Chi- squared tests for normal distributed 
continuous, non- normal distributed continuous, and categorical 
distributed baseline variables, respectively.
Model input parameters
Online supplemental table S1 in the online supplementary mate-




Online supplemental table S2 contains descriptive statistics 
of 2892 MR CLEAN registry patients per hour of delay from 
onset to groin puncture. Age, clinical (NIHSS), and radiological 
(ASPECTS) parameters were significantly associated with delay 
to EVT. The proportion of directly referred patients was signifi-
cantly lower in the 4th–6th hours of delay from onset to groin 
puncture. Furthermore, intravenous thrombolysis was admin-
istered to 77.4%, and 61.3% of the entire population were 
directly referred to an EVT- capable center.
Baseline simulations and one-way sensitivity analyses
Costs per hour of delay remained roughly equal, while QALYs 
and thus NMV decreased (online supplemental table S3). Each 
minute of faster EVT resulted in an NMB of €242 (per hour: 
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€14,519). This was mainly due to a 1.4 gain of disability free 
life- days (0.224 QALYs per hour). Costs changed with -€41 per 
minute of faster EVT (per hour: -€2,433).
The one- way sensitivity analysis revealed that age at the start 
of simulations, QALYs per year in mRS 0–4, and costs per year 
in mRS 3–4 affect NMB most. Costs in the first year in mRS 2–4 
affected NMB more than costs made in the subsequent 4 years, 
except for costs in mRS 4. Online supplemental figure S1 in the 
online supplementary material depicts the one- way sensitivity 
analyses results.
Probabilistic sensitivity analysis
Similar to the baseline simulation results, costs remained stable 
while QALYs and thus NMV decreased per hour of delay in 
the PSA (figure 3). Faster EVT resulted in no change in costs 
(per minute median: -€15, IQR: -€65;€33 – per hour median: 
-€969, IQR: -€3,897;€1,972), a gain in health (per minute 
disability- free life- days gained median: 1.3, IQR: 1.0;1.6 – per 
hour QALYs gained median: 0.22, IQR: 0.17;0.27), resulting in 
a positive NMB (per minute median: €309, IQR: €226;389 – 
per hour median: €18 513 IQR: €13,574;€23,376). Results of 
faster EVT for differences between separate hours of time to 
groin and the outcome for the Dutch population are depicted 
in table 1. Faster EVT between the third and fourth hour had 
a more profound effect on disability- free life- days and NMB. 
For an expected number of 887 EVT- eligible AIS patients in the 
Dutch population yearly, delivery of EVT by 1 min faster would 
result in a median QALY gain of 3.5 (IQR: 2.1;4.9 – per hour 
median: 210.1, IQR: 124.0;294.8), and a per minute median 
NMB of €287 324 (IQR: €146,270;€428,547 – per hour 
median: €17,239,435, IQR: €8,776,181;€25,712,803).
External validation of simulated MRS distributions
In online supplemental figure S2 in the online supplementary 
material the external validation results are depicted. Good func-
tional outcome (mRS ≤2; online supplemental figure S2A) and 
mortality (mRS 6; online supplemental figure S2C) at 1 and 2 
years were comparable with results from the REVASCAT and 
MR CLEAN follow- up studies.23 29 Observed values were similar 
to simulated values of 3- hour delay to groin puncture. Mortality 
(mRS 6; online supplemental figure S2C) at 5= year follow- up 
was higher in the simulated data compared with the study by 
Clua- Espuny et al.30
DISCUSSION
Delay of time from onset to groin puncture results in a loss of 
health (QALYs) that accumulates over the years following an 
acute LVO stroke setting. Faster EVT will result in a gain in 
health, while costs from a healthcare payer perspective remain 
stable. Thus, faster EVT is cost effective. We have indicated that 
an NMB of €309 per minute faster EVT may be achieved, which, 
extrapolated to the Dutch population, equals an annual NMB 
of €287 324. Since the treatment effect of EVT in the Dutch 
MR CLEAN trial and Registry was lower than that of its inter-
national peers, it seems likely that the NMB per minute faster 
EVT is even higher in populations with higher treatment effect 
of EVT.
Even though only the potential benefits and not the costs 
of realizing faster EVT were considered, this study provides a 
strong argument to invest more in stroke logistics. Depending on 
the approach to realize faster EVT it seems likely that additional 
costs will be made. For example, better ambulance coverage or 
Figure 3 Probabilistic sensitivity analysis results per hour of delay 
from onset to groin puncture: Costs (A), quality- adjusted life- year 
(QALY) (B), and Net Monetary Value (C) per hour time from onset to 
groin puncture.
Table 1 Probabilistic sensitivity analysis results per hour of faster treatment
Hour difference Costs in € median (IQR) QALY gained median (IQR) NMB in € median (IQR)
First – second hour 2633 (−10,957;18,613) 0.36 (0.09;0.61) 23 799 (−3004;49,133)
Second – third hour −2219 (−6,651;2,240) 0.15 (0.07;0.23) 14 052 (6,809;21,714)
Third – fourth hour −3228 (−7,274;1,026) 0.34 (0.28;0.40) 30 143 (23,732;36,679)
Fourth – fifth hour 4666 (440;9,078) 0.22 (0.16;0.29) 13 125 (6,353;19,682)
Fifth – sixth hour −3860 (−10,108;2,261) 0.09 (−0.01;0.18) 10 560 (1,708;19,971)
Per hour faster treatment* −969 (−3,897;1,972) 0.22 (0.17;0.27) 18 513 (13,574;23,376)
Per 10 min faster treatment* −151 (−649; 329) 13.5 (10.5;16.4)† 3085 (2,262;3,896)
Per minute faster treatment* −15 (−65;33) 1.3 (1.0;1.6)† 309 (226;389)
Population outcome per hour of earlier treatment‡ −865,387 (−5,848,900;4,459,552) 210.1 (124.0;294.8) 17 239 435 (8,776,181;25,712,803)
Population outcome per 10 min of earlier treatment‡ −144,231 (−974,817;743,258) 35.0 (20.7;49.1) 2 873 239 (1,462,696;4,285,467)
Population outcome per minute of earlier treatment§ −14,423 (−97,482;74,326) 3.5 (2.1;4.9) 287 324 (146,270;428,547)
*For each simulation the median value of the five differences between 6 hours was taken.
†The per minute QALY results are depicted as disability- free life days gained (DALY). This is the daily value of a QALY (DALY=QALY/365).
‡Outcome for the Dutch LVO stroke population if faster EVT is performed.
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public awareness of stroke symptoms might be used for faster 
EVT delivery, which requires investments in ambulance coverage 
and educational programs that are not included in this study. 
Furthermore, it should be considered that in per euro invested in 
expediting EVT there might be diminishing returns with respect 
to the realized minutes of faster EVT.
The paradox of higher lifetime healthcare costs due to longer 
survival caused no cost savings as a result of faster EVT in this 
study. Patients with faster EVT had an improved functional 
outcome (mRS) and life expectancy, however, additional health-
care costs were made in the long term. Faster EVT in the popu-
lation treated between the third and fourth hour of onset to 
groin puncture was related to a larger health effect than that of 
differences between other hours. This could be related to the 
proportion of directly referred patients to an EVT- capable stroke 
center (online supplemental table S2): a potential selection of 
indirectly referred patients could have occurred. Although a 
clear relationship between faster EVT and NMB was found, this 
result was very sensitive to age. An increase in age resulted in 
an exponential decrease of the cost effectiveness of faster EVT 
in terms of NMB, which is in line with the findings by Wu et al 
where the cost effectiveness of reperfusion after EVT decreased 
with an increase in age.31 In addition, the effect of age in this 
study is likely to be an underestimation since the modeled effect 
of age only considered mRS changes in the long run (after 90 
days' post- stroke), whereas it is known that age is also related to 
poor functional outcome at 90 days.4
Findings from this study are in accordance with the US- based 
population study by Kunz et al,14 and the indirect effect of time 
on the cost- effectiveness analyses for M2 occlusions by Khunte 
et al.32 The exact quantitative value of faster EVT was, however, 
much less (NMB median: $1,059; 95% prediction interval: 
$555-$1,485) than the study by Kunz et al. This difference in 
NMB per minute of faster EVT was mainly due to differences 
in follow- up simulation time and cost computations: Kunz et 
al used life- time simulations and included both societal and 
healthcare costs, while 5- year follow- up and only direct health-
care costs were used in this study. This timespan was chosen to 
retrieve a more conservative and certain estimation of the value 
of time, since the simulation of longer follow- up results in the 
accumulation of probability estimate errors. Kunz et al also 
found that age was the major factor affecting NMB of faster 
treatment.14 The comparison of simulated results with observed 
long- term mRS distributions revealed a comparable proportion 
of good functional outcome but a higher mortality rate in the 
baseline simulations than observed rates in the validation studies 
considered.23 29 30 Although this might implicate an overes-
timated mortality rate, a lower age in two of three validation 
studies (age in Clua- Espuny et al30; MR CLEAN; REVASCAT: 
69.5;65.5;67.2) could explain the lower mortality rate in these 
studies. In addition, these validation studies either were retro-
spective in design and thus prone to selection bias (Clua- Espuny 
et al30), had a large loss to follow- up (MR CLEAN, 16.7%), or 
had a relatively low sample size (REVASCAT, n=103).
The lack of data regarding the long- term decline of mRS, 
stroke recurrence, and mortality in patients with LVO under-
going EVT remains a shortcoming of this study. If survival and 
time in different mRS states differ in the long- run costs and 
health effects also alter significantly. Another limitation of this 
study was the lack of recent data on healthcare spending after 
a 2- year follow- up period and societal costs. To improve the 
accuracy of cost- effectiveness studies in stroke, future research 
should aim at retrieving better cost estimates from a healthcare 
payer and societal perspective related to mRS during multiple 
years after an initial stroke. However, if the relative cost differ-
ences related to the mRS Markov states remain similar, it is in 
the line of expectation that the results of this study would not 
differ. Furthermore, mRS decline and mortality related to mRS 
in time should be studied more extensively.
The results of this study should be seen as the potential benefit 
of faster EVT at a population level: 1 min of faster EVT does not 
necessarily benefit every patient equally. Since age has a large 
effect on the cost effectiveness of faster treatment, the extrap-
olation of findings from this study to other, potentially much 
older, populations should be performed with caution. Further-
more, the high percentage of direct referral to an EVT- capable 
center and intravenous thrombolysis administration were not 
included in this study. Deviations of those percentages in other 
populations might result in a different EVT treatment effect/
time relationship which, in turn, affects cost effectiveness and 
clinical outcomes. However, randomized controlled trial- based 
cost effectiveness analyses are required to determine the rela-
tionship between direct referral to EVT- capable centers, throm-
bolysis administration, and faster EVT. Nevertheless, we believe 
that with the available (public) information this study gives a 
fine- grained representation of mRS and a conservative cost and 
health effect estimate that stresses the necessity for healthcare 
payers to extensively invest in faster EVT delivery.
CONCLUSION
Saving time to groin puncture has the potential to improve 
health while healthcare costs may be expected to remain stable 
over 5- year follow- up. At a willingness to pay of €80 000 per 
QALY, 1 min of faster treatment is equivalent to 1.3 disability- 
free life- days saved and a NMB of €309 in a median 69- year- old 
Dutch population.
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